Overview

Study of the Electrocardiographic Effects of TA-8995

Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
A study in healthy males and females to see if a high single dose of TA-8995 has an effect on the ECG QTcF interval.
Phase:
Phase 1
Details
Lead Sponsor:
Xention Ltd
Treatments:
Fluoroquinolones
Moxifloxacin
Norgestimate, ethinyl estradiol drug combination